PHASE II STUDY OF EVEROLIMUS (E) IN REFRACTORY GERM CELL TUMORS (GCTS)

被引：0
|
作者：
Reckova, M. [1 ]
Mego, M. [1 ]
Svetlovska, D. [1 ]
Miskovska', V. [2 ]
Obertova, J. [1 ]
Sycova-Mila, Z. [1 ]
Palacka, P. [1 ]
Rajec, J. [1 ]
Liskova, S. [1 ]
Mardiak, J. [1 ]
机构：
[1] Natl Canc Inst, Bratislava, Slovakia
[2] St Elisabeth Canc Inst, Bratislava, Slovakia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：293 / 293
页数：1
相关论文
共 50 条
  • [1] Phase II study of everolimus (E) in refractory germ cell tumors (GCTs).
    Mego, Michal
    Svetlovska, Daniela
    Obertova, Jana
    Reckova, Maria
    Miskovska, Viera
    Rajec, Jan
    Sycova-Mila, Zuzana
    Palacka, Patrik
    Liskova, Stefania
    Chovanec, Michal
    Salek, Tomas
    Mardiak, Jozef
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Phase II study of everolimus (E) in refractory testicular germ cell tumors (TGCTs)
    Mego, Michal
    Svetlovska, Daniela
    Miskovska, Vera
    Obertova, Jana
    Zuzak, Peter
    Palacka, Patrik
    Rajec, Jan
    Sycova-Mila, Zuzana
    Chovanec, Michal
    Reckova, Maria
    Rejlekova, Katarina
    Ondrus, Dalibor
    Spanik, Stanislav
    Mardiak, Jozef
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Phase II study of everolimus in refractory testicular germ cell tumors
    Mego, Michal
    Svetlovska, Daniela
    Miskovska, Vera
    Obertova, Jana
    Palacka, Patrik
    Rajec, Jan
    Sycova-Mila, Zuzana
    Chovanec, Michal
    Rejlekova, Katarina
    Zuzak, Peter
    Ondrus, Dalibor
    Spanik, Stanislav
    Reckova, Maria
    Mardiak, Jozef
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (03) : 122.e17 - 122.e22
  • [4] Phase II study of disulfiram (D) and cisplatin (P) in refractory germ cell tumors (GCTs).
    Mego, Michal
    Svetlovska, Daniela
    Schmidtova, Silvia
    Kalavska, Katarina
    Obertova, Jana
    Palacka, Patrik
    De Angelis, Valentina
    Lesko, Peter
    Orszaghova, Zuzana
    Rejlekova, Katarina
    Reckova, Maria
    Sycova-Mila, Zuzana
    Mardiak, Jozef
    Chovanec, Michal
    Kucerova, Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17013 - E17013
  • [5] Phase II study of gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumors (GCTs).
    Mego, Michal
    Svetlovska, Daniela
    Reckova, Maria
    Kalavska, Katarina
    Obertova, Jana
    Palacka, Patrik
    Rejlekova, Katarina
    De Angelis, Valentina
    Sycova-Mila, Zuzana
    Chovanec, Michal
    Mardiak, Jozef
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs).
    Feldman, D. R.
    Einhorn, L. H.
    Quinn, D. I.
    Horwich, A.
    Loriot, Y.
    Joffe, J. K.
    Vaughn, D. J.
    Flechon, A.
    Hajdenberg, J.
    Pande, A. U.
    Liu, K.
    Gorbatchevsky, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Phase II study of sunitinib malate in refractory germ cell tumors.
    Reckova, M.
    Mego, M.
    Sycova-Mila, Z.
    Obertova, J.
    Svetlovska, D.
    Mardiak, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase II trial of paclitaxel in refractory germ cell tumors
    Sandler, AB
    Cristou, A
    Fox, S
    Williams, SD
    Nichols, CR
    Turns, M
    Roth, BJ
    CANCER, 1998, 82 (07) : 1381 - 1386
  • [9] Phase II trial of gemcitabine in refractory germ cell tumors
    Einhorn, LH
    Stender, MJ
    Williams, SD
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 509 - 511
  • [10] A phase II study of sirolimus and erlotinib in recurrent/refractory germ cell tumors.
    Laetsch, Theodore Willis
    Kumar, Kirthi
    Rakheja, Dinesh
    Wickiser, Jonathan E.
    Rodriguez-Galindo, Carlos
    Frazier, A. Lindsay
    Amatruda, James
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345